Drugs / KIN-3248
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05242822 | Mar 2022 → Oct 2024 | intrahepatic cholangiocarcinoma, urothelial carcinoma | Kinnate Biopharma | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIN-3248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05242822 ↗ |
| Action | Inhibit | “FGFR inhibitor” NCT05242822 ↗ |
| Modality | Small molecule | “an oral small molecule FGFR inhibitor” NCT05242822 ↗ |
| Route | Oral | “KIN-3248 will be administered orally once daily in 28-day cycles” NCT05242822 ↗ |